Skip to main content
Caplight Logo









Exosomics S.p.A.

Exosomics S.p.A.

Private
SienaHealthcare & Life Scienceshttps://www.exosomics.eu/

Last Round

Early Funding

May 16, 2017

Company Overview

Exosomics S.p.A. operates in Healthcare & Life Sciences and is based in Siena. Its latest recorded funding round was an Early Funding round in May 2017.

Exosomics S.p.A. is a biotechnology company that develops exosome-based liquid biopsy technologies and diagnostic tests for cancer screening and monitoring.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Exosomics S.p.A. Comparables

Compare Exosomics S.p.A. with similar companies based on industry and business-model similarity.

Exosomics S.p.A. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CellBio Scientific
81%
EValuate Diagnostics, Inc.
80%
Theoria Science, Inc.
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Exosomics S.p.A. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingMay 16, 2017
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors grew 869% MoM, from 35 to 339.

Book a demo to see all signals

For institutional investors. Book with your work email.

Exosomics S.p.A. Filings

Explore SEC and related filing metadata, where available.

Exosomics S.p.A. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Exosomics S.p.A.'s valuation, stock price, and market status.

Is Exosomics S.p.A. a public or private company?

Exosomics S.p.A. is a private company.

What is the current stock price of Exosomics S.p.A.?

Exosomics S.p.A. is a private company, so its shares have no public market price. Caplight tracks Exosomics S.p.A.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Exosomics S.p.A. worth (valuation)?

Valuation information for Exosomics S.p.A. is not publicly available.

Can I buy Exosomics S.p.A. stock?

Exosomics S.p.A. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Exosomics S.p.A.'s last funding round?

Exosomics S.p.A.'s most recent funding round was Early Funding on May 16, 2017.

Who are the main investors in Exosomics S.p.A.?

Investor information for Exosomics S.p.A. is not publicly disclosed.

Will Exosomics S.p.A. IPO soon?

No public IPO plans have been announced for Exosomics S.p.A..

How can I track Exosomics S.p.A. secondary market activity?

Caplight tracks bids, offers, and trades in Exosomics S.p.A.'s shares on secondary markets.

Firmographic Details

HeadquartersSiena
Employee Range1
Year Founded2011
Last FundingMay 16, 2017

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?